$0.69
0.22%
NYSE, Tue, Aug 12 2025
ISIN
US2941001024
Symbol
ENZ

Enzo Biochem, Inc. Stock price

$0.69
+0.01 1.39% 1M
+0.22 45.44% 6M
-0.02 3.12% YTD
-0.36 34.10% 1Y
-1.98 74.08% 3Y
-1.77 71.87% 5Y
-2.35 77.24% 10Y
-14.51 95.45% 20Y
NYSE, Closing price Tue, Aug 12 2025
+0.00 0.22%

Key metrics

Basic
Market capitalization
$35.8m
Enterprise Value
$-4.3m
Net debt
positive
Cash
$40.3m
Shares outstanding
52.4m
Valuation (TTM | estimate)
P/E
negative | -
P/S
1.2 | -
EV/Sales
negative | -
EV/FCF
0.3
P/B
0.8
Financial Health
Equity Ratio
65.4%
Return on Equity
-46.5%
ROCE
-16.5%
ROIC
-51.0%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$29.1m | -
EBITDA
$-7.0m | -
EBIT
$-8.3m | -
Net Income
$-21.3m | -
Free Cash Flow
$-15.8m
Growth (TTM | estimate)
Revenue
-54.2% | -
EBITDA
80.1% | -
EBIT
77.3% | -
Net Income
-365.3% | -
Free Cash Flow
65.7%
Margin (TTM | estimate)
Gross
44.7%
EBITDA
-23.9% | -
EBIT
-28.6%
Net
-73.3% | -
Free Cash Flow
-54.1%
More
EPS
$-0.4
FCF per Share
$-0.3
Short interest
0.8%
Employees
131
Rev per Employee
$240.0k
Show more

Is Enzo Biochem, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Enzo Biochem, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Enzo Biochem, Inc. forecast:

4x Buy
80%
1x Hold
20%

Analyst Opinions

5 Analysts have issued a Enzo Biochem, Inc. forecast:

Buy
80%
Hold
20%

Financial data from Enzo Biochem, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jan '25
+/-
%
29 29
54% 54%
100%
- Direct Costs 16 16
62% 62%
55%
13 13
38% 38%
45%
- Selling and Administrative Expenses 19 19
63% 63%
66%
- Research and Development Expense 2.25 2.25
64% 64%
8%
-6.96 -6.96
80% 80%
-24%
- Depreciation and Amortization 1.37 1.37
23% 23%
5%
EBIT (Operating Income) EBIT -8.33 -8.33
77% 77%
-29%
Net Profit -21 -21
365% 365%
-73%

In millions USD.

Don't miss a Thing! We will send you all news about Enzo Biochem, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Enzo Biochem, Inc. Stock News

Neutral
GlobeNewsWire
about 2 months ago
Transaction Follows Completion of Comprehensive Strategic Review by Special Committee of the Board to Maximize Shareholder Value
Neutral
GlobeNewsWire
about 2 months ago
FARMINGDALE, N.Y., June 16, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (OTCQX: ENZB) (“Enzo” or the “Company”) today announced financial results for the fiscal third quarter ended April 30, 2025.
Neutral
GlobeNewsWire
4 months ago
Forms Special Committee of the Board to Lead Evaluation of Viable Options for Maximizing Shareholder Value
More Enzo Biochem, Inc. News

Company Profile

Enzo Biochem, Inc. engages in the development, manufacture and sale of technology solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians globally. It operates through the following segments: Enzo Clinical Laboratory Services, Enzo Life Sciences Products, and Enzo Therapeutics. The Enzo Clinical Laboratory Services segment includes clinical reference laboratory providing a wide range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. The Enzo Life Sciences Products segment manufactures, develops and markets products and tools for clinical research, drug development and bioscience research customers worldwide. The Enzo Therapeutics segment develops multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases, many of which are derived from the pioneering work of Enzo Life Sciences. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in 1976 and is headquartered in New York, NY.

Head office United States
CEO Kara Cannon
Employees 131
Founded 1976
Website www.enzo.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today